Search

Your search keyword '"Zhugunissov, Kuandyk"' showing total 17 results
Start Over Author "Zhugunissov, Kuandyk"
Sorry, I don't understand your search. ×
17 results on '"Zhugunissov, Kuandyk"'

1. Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in®, in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up

Author

Khairullin, Berik, Zakarya, Kunsulu, Orynbayev, Mukhit, Abduraimov, Yergali, Kassenov, Markhabat, Sarsenbayeva, Gulbanu, Sultankulova, Kulyaisan, Chervyakova, Olga, Myrzakhmetova, Balzhan, Nakhanov, Aziz, Nurpeisova, Ainur, Zhugunissov, Kuandyk, Assanzhanova, Nurika, Nurabayev, Sergazy, Kerimbayev, Aslan, Yershebulov, Zakir, Burashev, Yerbol, Kulmagambetov, Ilyas, Davlyatshin, Timur, Sergeeva, Maria, Buzitskaya, Zhanna, Stukova, Marina, and Kutumbetov, Lespek

Published
2022
Full Text
View/download PDF

2. Safety and Immunogenicity of the Live Attenuated Vaccine QazCOVID-Live Against Coronavirus Infection COVID-19: Pre-Clinical Study Results.

Author

Kutumbetov, Lespek, Myrzakhmetova, Balzhan, Tussipova, Aiganym, Zhapparova, Gulzhan, Tlenchiyeva, Talshyngul, Bissenbayeva, Karina, Zhapar, Kuanysh, Zhugunissov, Kuandyk, Nurabayev, Sergazy, and Kerimbayev, Aslan

Subjects
COVID-19, INTRANASAL administration, DELAYED hypersensitivity, GUINEA pigs, VACCINE safety
Abstract

The research conducted in this preclinical study assesses QazCovid-live, a live attenuated COVID-19 vaccine created in Kazakhstan, by conducting preclinical evaluations of safety, immunogenicity, and allergenicity in various animal models, including mice, rats, hamsters, and guinea pigs. The vaccine, developed by attenuating SARS-CoV-2 via numerous Vero cell passages, had no significant adverse effects in acute and subacute toxicity assessments, even at elevated dosages. Allergenicity testing indicated the absence of both immediate and delayed hypersensitivity reactions. Immunogenicity evaluations revealed strong virus-neutralizing antibody responses, especially following intranasal and intratracheal delivery. Studies on reversibility and transmission further validated the vaccine's stability and non-pathogenicity. The data indicate that QazCovid-live is safe, immunogenic, and prepared for clinical trials, presenting a potential strategy for COVID-19 prevention. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Field Trials of Live and Inactivated Camelpox Vaccines in Kazakhstan.

Author

Mambetaliyev, Muratbay, Kilibayev, Sanat, Kenzhebaeva, Marzhan, Sarsenkulova, Nuraiym, Tabys, Shalkar, Valiyeva, Aisulu, Muzarap, Dias, Tuyskanova, Moldir, Myrzakhmetova, Balzhan, Rametov, Nurkuisa, Sarbassova, Aizhamal, Nurgaziev, Ryspek, Kerimbayev, Aslan, Babiuk, Shawn, and Zhugunissov, Kuandyk

Subjects
FIELD research, VACCINE effectiveness, VACCINE immunogenicity, HIV seroconversion, VACCINE trials, VACCINES
Abstract

An outbreak of camelpox occurred in the Mangistau region of Kazakhstan in 2019. To control the outbreak of camelpox and to prevent its further spread to other regions, camels were vaccinated using live and inactivated camelpox vaccines produced in Kazakhstan. To evaluate the efficacy of these camelpox vaccines in the field, vaccine trials used 172 camels on camel farms in the Beineu district. Of these, 132 camels were vaccinated using a live attenuated camelpox vaccine and 40 camels were vaccinated using an inactivated vaccine to observe immunogenicity and safety. The live vaccine was inoculated into camels by scarification at a dose of 5 × 104 EID50, and the inactivated vaccine was injected intramuscularly at 5 mL twice, with an interval of 35 days. During the safety evaluation, camels administered either vaccine displayed no clinical signs of illness or any adverse effects. Post-vaccination seroconversion demonstrated that the live attenuated vaccine started to elicit antibody responses in some animals as early as day seven, while, by day 28, 99% of vaccinated camels responded. For camels immunized with the inactivated vaccine, seroconversion began on day 21 at low titers ranging from 1:2 to 1:4. Ninety days post vaccination, 77% of the camels demonstrated an immune response that was up to a titer of 1:16. The antibody response waned six months post vaccination in camels vaccinated with two types of vaccine. Nonetheless, both vaccines were 100% effective at preventing clinical disease in vaccinated camels during the camelpox outbreak. All unvaccinated camels became ill, with manifestations of clinical signs characteristic of camelpox. Following these successful field trials in Kazakhstan, a vaccination program for camels, to control camelpox using the domestically produced live attenuated camelpox vaccine, has started. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. In Vitro Fertilization in Kazakh Whiteheaded Cattle: A Comparative Study

Author

Seisenov, Bolat, primary, Duimbayev, Dulat, additional, Kazhgaliyev, Nurlybay, additional, Abdrakhmanov, Talgat, additional, Tegza, Alexandra, additional, Abeldinov, Rustem, additional, Burambayeva, Nadezhda, additional, Temirzhanova, Alma, additional, Tegza, Ivan, additional, Kemeshev, Zhomart, additional, Zhanabayev, Assylbek, additional, Akhmetbekov, Nurbolat, additional, Aisin, Marat, additional, Zhugunissov, Kuandyk, additional, and Issimov, Arman, additional

Published
2023
Full Text
View/download PDF

7. Sars-Cov-2 Virus Pathogenicity in Syrian Hamsters at Different Routes of Inoculation

Author

TUYSKANOVA, Moldir, primary, ZHUGUNISSOV, Kuandyk, additional, OZASLAN, Mehmet, additional, NAKHANOV, Aziz, additional, ZAKARYA, Kunsulu, additional, AZANBEKOVA, Moldir, additional, KENZHEBAEVA, Marzhan, additional, OMURTAY, Alisher, additional, DZHAPASHEVA, Arailym, additional, MAMBETALIYEV, Muratbay, additional, TABYS, Shalkar, additional, MYRZAKHMETOVA, Balzhan, additional, and KUTUMBETOV, Lespek, additional

Published
2022
Full Text
View/download PDF

8. Near-Complete Genome Sequence of a SARS-CoV-2 Variant B.1.1.7 Virus Strain Isolated in Kazakhstan

Author

Usserbayev, Bekbolat, primary, Zakarya, Kunsulu, additional, Kutumbetov, Lespek, additional, Orynbaуev, Mukhit, additional, Sultankulova, Kulyaisan, additional, Abduraimov, Yergali, additional, Myrzakhmetova, Balzhan, additional, Zhugunissov, Kuandyk, additional, Kerimbayev, Aslan, additional, Melisbek, Aibarys, additional, Shirinbekov, Meiіrzhan, additional, Khaidarov, Saken, additional, Zhunushov, Asankadyr, additional, and Burashev, Yerbol, additional

Published
2022
Full Text
View/download PDF

10. Efficacy and Safety of an Inactivated Whole-Virion Vaccine Against COVID-19, QazCovid-in®, In Healthy Adults: A Multicentre, Randomised, Single-Blind, Placebo-Controlled Phase 3 Clinical Trial With a 6-Month Follow-Up

Author

Khairullin, Berik, primary, Zakarya, Kunsulu, additional, Orynbayev, Mukhit, additional, Abduraimov, Yergali, additional, Kassenov, Markhabat, additional, Sarsenbayeva, Gulbanu, additional, Sultankulova, Kulyaisan, additional, Cherviyakova, Olga, additional, Myrzhakhmetova, Balzhan, additional, Nakhanov, Aziz, additional, Nurpeisova, Ainur, additional, Zhugunissov, Kuandyk, additional, Assanzhanova, Nurika, additional, Nurabayev, Sergazy, additional, Kerimbayev, Aslan, additional, Ershebulov, Zakir, additional, Burashev, Yerbol, additional, Kulmagambetov, Ilyas, additional, Davlyatshin, Timur, additional, Sergeeva, Maria, additional, Buzitskaya, Zhanna, additional, Stukova, Marina, additional, and Kutumbetov, Lespek, additional

Published
2022
Full Text
View/download PDF

11. Development of the Inactivated QazCovid-in Vaccine: Protective Efficacy of the Vaccine in Syrian Hamsters

Author

Zhugunissov, Kuandyk, primary, Zakarya, Kunsulu, additional, Khairullin, Berik, additional, Orynbayev, Mukhit, additional, Abduraimov, Yergali, additional, Kassenov, Markhabat, additional, Sultankulova, Kulyaisan, additional, Kerimbayev, Aslan, additional, Nurabayev, Sergazy, additional, Myrzakhmetova, Balzhan, additional, Nakhanov, Aziz, additional, Nurpeisova, Ainur, additional, Chervyakova, Olga, additional, Assanzhanova, Nurika, additional, Burashev, Yerbol, additional, Mambetaliyev, Muratbay, additional, Azanbekova, Moldir, additional, Kopeyev, Syrym, additional, Kozhabergenov, Nurlan, additional, Issabek, Aisha, additional, Tuyskanova, Moldir, additional, and Kutumbetov, Lespek, additional

Published
2021
Full Text
View/download PDF

12. Development and Evaluation of a Live Attenuated Egg-Based Camelpox Vaccine

Author

Zhugunissov, Kuandyk, primary, Kilibayev, Sanat, additional, Mambetaliyev, Muratbay, additional, Zakarya, Kunsulu, additional, Kassenov, Markhabat, additional, Abduraimov, Yergaliy, additional, Bulatov, Yerbol, additional, Azanbekova, Moldir, additional, Absatova, Zharkinay, additional, Abeuov, Khairulla, additional, Nurgaziev, Ryspek, additional, Renukaradhya, Gourapura J., additional, and Tabynov, Kairat, additional

Published
2021
Full Text
View/download PDF

13. Duration of Protective Immunity in Sheep Vaccinated with a Combined Vaccine against Peste des Petits Ruminants and Sheep Pox

Author

Amanova, Zhanat, primary, Zhugunissov, Kuandyk, additional, Barakbayev, Kainar, additional, Kondybaeva, Zhanat, additional, Sametova, Zhanna, additional, Shayakhmetov, Yeraly, additional, Kaissenov, Dastan, additional, Dzhekebekov, Kuanysh, additional, Zhunushov, Asankadyr, additional, Abduraimov, Yergaly, additional, Zakarya, Kunsulu, additional, and Bulatov, Yerbol, additional

Published
2021
Full Text
View/download PDF

14. The combined effects of temperature and relative humidity parameters on the reproduction of Stomoxys species in a laboratory setting

Author

Issimov, Arman, primary, Taylor, David B., additional, Zhugunissov, Kuandyk, additional, Kutumbetov, Lespek, additional, Zhanabayev, Assylbek, additional, Kazhgaliyev, Nurlybay, additional, Akhmetaliyeva, Aliya, additional, Nurgaliyev, Birzhan, additional, Shalmenov, Malik, additional, Absatirov, Gaisa, additional, Dushayeva, Laura, additional, and White, Peter J., additional

Published
2020
Full Text
View/download PDF

15. Emergence of the First Lumpy Skin Disease Outbreak Among Livestock in the Republic of Kazakhstan in 2016.

Author

Issimov, Arman, primary, Rametov, Nurkuisa, additional, Zhugunissov, Kuandyk, additional, Kutumbetov, Lespek, additional, Zhanabayev, Assylbek, additional, Kazhgaliyev, Nurlybay, additional, Nurgaliyev, Birzhan, additional, Shalmenov, Malik, additional, Absatirov, Gaisa, additional, Dushayeva, Laura, additional, Akhmetaliyeva, Aliya, additional, Kereyev, Abzal, additional, and White, Peter, additional

Published
2020
Full Text
View/download PDF

16. Corrigendum to ‘Beta-propiolactone inactivated bivalent bluetongue virus vaccine containing montanide ISA-71VG adjuvant induces long-term immune response in sheep against serotypes 4 and 16 even after 3 years of controlled vaccine storage’ [Vet. Microbiol. 226 (2018) 23–30]

Author

Zhugunissov, Kuandyk, primary, Bulatov, Yerbol, additional, Taranov, Dmitriy, additional, Yershebulov, Zakir, additional, Koshemetov, Zhumagali, additional, Zhunushov, Asankadyr, additional, Renukaradhya, Gourapura J., additional, Tabynov, Kaissar, additional, and Abduraimov, Yergali, additional

Published
2019
Full Text
View/download PDF

17. Beta-propiolactone inactivated bivalent bluetongue virus vaccine containing Montanide ISA-71VG adjuvant induces long-term immune response in sheep against serotypes 4 and 16 even after 3 years of controlled vaccine storage

Author

Zhugunissov, Kuandyk, primary, Bulatov, Yerbol, additional, Taranov, Dmitriy, additional, Yershebulov, Zakir, additional, Koshemetov, Zhumagali, additional, Zhunushov, Asankadyr, additional, Renukaradhya, Gourapura J., additional, Tabynov, Kaissar, additional, and Abduraimov, Yergali, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results